Genetics of melanoma predisposition

British Journal of Dermatology

Volumn 159, Issue 2, 2008, Pages 286-291

  Lin, J ^a   Hocker, T L ^a   Singh, M ^a   Tsao, H ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Genetics; Melanoma

Indexed keywords

AROMATASE INHIBITOR; DICLOFENAC; FIBRIC ACID DERIVATIVE; FINASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOID DERIVATIVE; TAMOXIFEN; VITAMIN;

ACTINIC KERATOSIS; BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CDK4 GENE; CDK6 GENE; CDKN2A GENE; CHEMOPROPHYLAXIS; COLON CANCER; GENE LOCUS; GENE MUTATION; GENETIC PROCEDURES; GENOTYPE; HUMAN; KERATINOCYTE; MELANOCORTIN 1 RECEPTOR GENE; MELANOMA; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MELANOMA; PEDIGREE; SKIN NEOPLASMS;

EID: 47549118838     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08682.x     Document Type: Review

References (57)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002 52 : 23 47.
2. Burton RC. Malignant melanoma in the year 2000. CA Cancer J Clin 2000 50 : 209 13.
3. Schaffer JV, Rigel DS, Kopf AW, Bolognia JL. Cutaneous melanoma - past, present, and future. J Am Acad Dermatol 2004 51 (Suppl. 1 S65 9.
4. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004 150 : 179 85.
5. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004 351 : 998 1012.
6. Dreiling L, Hoffman S, Robinson WA. Melanoma: epidemiology, pathogenesis, and new modes of treatment. Adv Intern Med 1996 41 : 553 604.
7. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001 19 : 3635 48.
8. de Snoo FA, Hayward NK. Cutaneous melanoma susceptibility and progression genes. Cancer Lett 2005 230 : 153 86.
9. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003 22 : 3053 62.
10. Fargnoli MC, Argenziano G, Zalaudek I, Peris K. High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Rev Anticancer Ther 2006 6 : 657 70.
11. Bishop JN, Harland M, Bishop DT. The genetics of melanoma. Br J Hosp Med (Lond) 2006 67 : 299 304.
12. Clark WH Jr, Reimer RR, Greene M et al. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol 1978 114 : 732 8.
13. Lynch HT, Frichot BC III, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978 15 : 352 6.
14. Tsao H, Sober AJ, Niendorf KB, Zembowicz A. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 7-2004. A 48-year-old woman with multiple pigmented lesions and a personal and family history of melanoma. N Engl J Med 2004 350 : 924 32.
15. Kamb A, Shattuck-Eidens D, Eeles R et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994 8 : 23 6.
16. Hussussian CJ, Struewing JP, Goldstein AM et al. Germline p16 mutations in familial melanoma. Nat Genet 1994 8 : 15 21.
17. Pollock PM, Harper UL, Hansen KS et al. High frequency of BRAF mutations in nevi. Nat Genet 2003 33 : 19 20.
18. Kefford R, Bishop JN, Tucker M et al. Genetic testing for melanoma. Lancet Oncol 2002 3 : 653 4.
19. Begg CB, Orlow I, Hummer AJ et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005 97 : 1507 15.
20. Soufir N, Avril MF, Chompret A et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998 7 : 209 16.
21. Zuo L, Weger J, Yang Q et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996 12 : 97 9.
22. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006 20 : 2149 82.
23. Goldstein AM. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 2004 23 : 630.
24. Rouzaud F, Kadekaro AL, Abdel-Malek ZA, Hearing VJ. MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res 2005 571 : 133 52.
25. Valverde P, Healy E, Jackson I et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995 11 : 328 30.
26. Box NF, Wyeth JR, O'Gorman LE et al. Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet 1997 6 : 1891 7.
27. Palmer JS, Duffy DL, Box NF et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000 66 : 176 86.
28. Kennedy C, ter Huurne J, Berkhout M et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001 117 : 294 300.
29. Box NF, Duffy DL, Chen W et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001 69 : 765 73.
30. Goldstein AM, Landi MT, Tsang S et al. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev 2005 14 : 2208 12.
31. Landi MT, Bauer J, Pfeiffer RM et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006 313 : 521 2.
32. Niendorf KB, Tsao H. Cutaneous melanoma: family screening and genetic testing. Dermatol Ther 2006 19 : 1 8.
33. Hansen CB, Wadge LM, Lowstuter K et al. Clinical germline genetic testing for melanoma. Lancet Oncol 2004 5 : 314 19.
34. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999 17 : 3245 51.
35. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003 57 : 23 9.
36. Dunn BK, Ford LG. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. Eur J Cancer Prev 2007 16 : 232 42.
37. Thompson IM, Lucia MS, Redman MW et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol 2007 178 : 107 9.
38. Veronesi U, Maisonneuve P, Rotmensz N et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003 95 : 160 5.
39. Vogel VG. Chemoprevention strategies 2006. Curr Treat Options Oncol 2007 8 : 74 88.
40. Morrow M, Jordan VC. The current status of breast cancer chemoprevention: a star is born. J Surg Oncol 2007 95 : 4 5.
41. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006 6 : 130 40.
42. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005 23 : 2840 55.
43. Nelson C, Rigel D, Smith S et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004 3 : 401 7.
44. Ulrich C, Hackethal M, Ulrich M et al. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br J Dermatol 2007 156 (Suppl. 3 40 2.
45. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003 9 : 10 19.
46. Graaf MR, Beiderbeck AB, Egberts AC et al. The risk of cancer in users of statins. J Clin Oncol 2004 22 : 2388 94.
47. Poynter JN, Gruber SB, Higgins PD et al. Statins and the risk of colorectal cancer. N Engl J Med 2005 352 : 2184 92.
48. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 279 : 1615 22.
49. Shellman YG, Ribble D, Miller L et al. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res 2005 15 : 83 9.
50. Freeman SR, Drake AL, Heilig LF et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst 2006 98 : 1538 46.
51. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999 341 : 410 18.
52. Francis SO, Mahlberg MJ, Johnson KR et al. Melanoma chemoprevention. J Am Acad Dermatol 2006 55 : 849 61.
53. Harris RE, Beebe-Donk J, Namboodiri KK. Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep 2001 8 : 655 7.
54. Berwick M, Armstrong BK, Ben-Porat L et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 2005 97 : 195 9.
55. Katiyar SK. Skin photoprotection by green tea: antioxidant and immunomodulatory effects. Curr Drug Targets Immune Endocr Metabol Disord 2003 3 : 234 42.
56. Halpern AC, Schuchter LM, Elder DE et al. Effects of topical tretinoin on dysplastic nevi. J Clin Oncol 1994 12 : 1028 35.
57. D'Orazio JA, Nobuhisa T, Cui R et al. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 2006 443 : 340 4.